ArticleJournal of extracellular vesicles2026
A Unique Intercellular Feedforward Loop From HK1 to TGF-β1 Promotes the Progression of Hepatocellular Carcinoma.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammation in hepatocellular carcinoma progression: a "Single Wick, dual interwoven strands" regulatory framework.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) typically emerges in a fibrotic premalignant liver milieu, and hepatic stellate cells (HSCs) represent the predominant cell subtype implicated in hepatic fibrosis. The crosstalk between HCC cells and HSCs has been demonstrated to affect HCC progression. Our prior research revealed that the activation of HSCs in hepatic fibrosis is accompanied with secretion of hexokinase 1 (HK1), an enzyme catalysing the initial step of glycolysis, through large extracellular vesicles (lEVs), which are selectively internalised by HCC cells to promote their glucose metabolism and tumour progression. In the present study, we found that the boosted glucose metabolism in HCC cells can reciprocally activate HSCs, thereby facilitating the formation of a pro-tumourigenic fibrotic microenvironment. Specifically, HSCs-transmitted lEV HK1 was identified as a key factor that markedly enhances the ability of HCC cells to activate HSCs. Mechanistically, HK1 accelerates the metabolic flux of hexosamine biosynthesis pathway, thereby promoting N-glycosylation of pro-transforming growth factor-β (TGF-β)1 and facilitating its secretion from HCC cells, which subsequently activates HSCs. This HCC cell-induced HSC activation is accompanied by increased secretion of lEV HK1 from HSCs, establishing a feedforward loop between HCC cells and HSCs. Furthermore, this intercellular communication was confirmed to exacerbate HCC progression in several mouse models, and disrupting this communication significantly inhibited HCC progression. Together, this study highlights that targeting the disruption of this feedforward loop may represent a promising and effective therapeutic strategy for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.